It is highly likely that the outcomes of combined ERα and p53 signalling in terms of proliferative or antiproliferative response will strongly depend upon the mutational, transcriptional and protein expression landscape of the particular tumour being targeted. The gene discussed is TP53; the disease is neoplasm.